Capsida Biotherapeutics Enters Into Strategic Collaboration With Eli Lilly’s Prevail To Develop Non-Invasive Gene Therapies For CNS Diseases

Capsida Biotherapeutics Inc. (Capsida) announced a multi-year strategic collaboration with Prevail Therapeutics (Prevail), a wholly owned subsidiary of Eli Lilly and Company (Lilly), to develop transformative genetic medicines for serious diseases. As part of the collaboration, Prevail will leverage Capsida's novel adeno-associated virus (AAV) engineering platform to identify and advance clinically translatable capsids paired with Prevail's cargo to develop best-in-class, IV-administered gene therapies directed to specified targets known to cause serious diseases that affect the central nervous system (CNS).

Delivering AAV gene therapy systemically to target the CNS, while limiting exposure to non . . .